

ASX Release

2 September 2024

Appointment of Chief Financial Officer

Melbourne, Australia – Tryptamine Therapeutics Limited (**'Tryp'** or the **'Company'**) (**ASX: TYP**), a clinical-stage biotechnology company is pleased to advise Mr Hamish George has been appointed Chief Financial Officer ('CFO'), effective 1 September 2024. As part of the appointment, previous CFO Mr Jim O'Neill has resigned.

Mr George is a Director at Bio101 Financial Advisory ('Bio101'), a financial services firm providing outsourced CFO, taxation and company secretarial solutions to the biotechnology and healthcare sector. He has over 10 years of finance and commercial experience working with public and private companies in Australia and abroad. Mr George currently serves as CFO and Company Secretary for several ASX-listed, private companies and not-for-profits. He holds a Bachelor of Commerce from the University of Melbourne, a Masters Degree in Professional Accounting from RMIT, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant.

The Board and management team look forward to leveraging Mr George's expertise in the biotechnology and healthcare sector as the Company advances its extensive clinical trial pathway utilising TRP-8802 (oral psilocybin) and TRP-8803 (IV-infused psilocin).

The Company would also like to take this opportunity to thank Mr Jim O'Neill for his service. Mr O'Neill performed his role as CFO admirably during his tenure and provided extensive expertise to management in the lead up to the Company's listing on the Australian Securities Exchange ('ASX') (refer ASX announcement: 29 May 2024). He also provided wide-ranging support to advance the transition of roles to Mr George during August 2024, enabling him to be fully engaged as CFO from 1 September 2024.

Management commentary:

Non-Executive Chairman, Mr Mark Davies said: *"On behalf of the Board, I would like to take this opportunity to welcome Hamish to the Company. As Tryp further establishes itself as a leading ASX-listed drug developer, the Board have made the strategic decision to align its resources accordingly and to this end, we look forward to working with someone of Hamish's calibre to further solidify our positioning."*

"I would also like to thank Mr Jim O'Neill for his contribution to the Company in the recent years. As CFO over the last three years, Jim has been instrumental in Tryp's development. He also provided extensive knowledge and support in the Company's transition to the ASX. The Board and management wish him well for his future endeavours."

This announcement has been authorised for release by the Board of Tryptamine Therapeutics Limited.

-ENDS-

About Tryptamine Therapeutics Limited

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp's lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has completed a Phase 2a



clinical trial for the treatment of binge eating disorder at the University of Florida, which demonstrated an average reduction in binge eating episodes of greater than 80%.

The Company also has also just completed a Phase 2a clinical trial for the treatment of fibromyalgia in collaboration with the University of Michigan and has initiated a Phase 2a clinical trial in collaboration with Massachusetts General Hospital for the treatment of abdominal pain and visceral tenderness in patients suffering from irritable bowel syndrome. Each of the studies is utilising TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications. Where a positive clinical response is demonstrated, subsequent studies are expected to utilise TRP-8803 (IV-infused psilocin), that has the potential to further improve efficacy, safety, and patient experience. TRP-8803 is currently being evaluated in a Phase 1 Healthy Volunteer Study in Adelaide, Australia.

For more information, please visit www.tryptherapeutics.com.

Investor & Media Contact

Jason Carroll
Chief Executive Officer
Tryptamine Therapeutics Limited
jcarroll@tryptherapeutics.com

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

Forward-Looking Information

Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp's Replacement Prospectus available at www.asx.com.au. These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.